Aktis Oncology, Inc. Common stock - Asset Resilience Ratio
Aktis Oncology, Inc. Common stock (AKTS) has an Asset Resilience Ratio of 23.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AKTS total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Aktis Oncology, Inc. Common stock's Asset Resilience Ratio has changed over time. See AKTS book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Aktis Oncology, Inc. Common stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Aktis Oncology, Inc. Common stock (AKTS) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $65.97 Million | 23.64% |
| Total Liquid Assets | $65.97 Million | 23.64% |
Asset Resilience Insights
- Good Liquidity Position: Aktis Oncology, Inc. Common stock maintains a healthy 23.64% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Aktis Oncology, Inc. Common stock Industry Peers by Asset Resilience Ratio
Compare Aktis Oncology, Inc. Common stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Aktis Oncology, Inc. Common stock (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Aktis Oncology, Inc. Common stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 79.71% | $260.01 Million | $326.18 Million | +23.85pp |
| 2023-12-31 | 55.86% | $68.35 Million | $122.36 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $138.32 Million | -- |
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more